Blockade of the CD47–SIRPα interaction synergizes with both tumor-specific antibodies and ICIs by effectively reprogramming the myeloid compartment toward a proinflammatory phenotype improving tumor cell phagocytosis, antigen presentation, and T cell priming [9, 13]. Here, SIRPA is linked to neoplasm.